- Conditions
- Chronic Inducible Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Interventions
- Lonapegsomatropin, Placebo, Somatropin
- Drug · Other
- Lead sponsor
- Ascendis Pharma Endocrinology Division A/S
- Industry
- Eligibility
- 23 Years to 80 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab, Placebo
- Biological
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
- Conditions
- BK Virus Infection, BKV Infection, Kidney Transplant
- Interventions
- AIC263029, Placebo
- Drug
- Lead sponsor
- AiCuris Anti-infective Cures AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 10 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Boca Raton, Florida • Gainesville, Florida • Iowa City, Iowa + 3 more
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency
- Interventions
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Marshfield, Wisconsin
- Conditions
- Crohn's Disease
- Interventions
- Abrilumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 20 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 13
- States / cities
- Fresno, California • Los Angeles, California • Montclair, California + 10 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2405319, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 7
- States / cities
- Cypress, California • Tustin, California • DeLand, Florida + 4 more
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Bococizumab (PF-04950615;RN316), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Hartford, Connecticut • Hialeah, Florida + 13 more
- Conditions
- Multiple Sclerosis
- Interventions
- diclofenac sodium topical gel, Placebo
- Drug · Other
- Lead sponsor
- Brown, Theodore R., M.D., MPH
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Tulisokibart, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
- Conditions
- Taste Sweet, Taste Salty, Feeding Behavior
- Interventions
- taste acuity assessment, Recorded meal
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- NNC9204-1706, Placebo (NNC9204-1706)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Giant Cell Arteritis
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 5
- States / cities
- Rochester, Minnesota • New York, New York • Cleveland, Ohio + 2 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Elafin, Placebo
- Drug
- Lead sponsor
- Roham T. Zamanian
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 79 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Abatacept, UST Placebo, ABA Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
- Conditions
- Childhood Obesity
- Interventions
- Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo
- Behavioral · Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Thrombocytopaenia
- Interventions
- Eltrombopag, Azacitidine, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Overweight, Obesity
- Interventions
- NNC0247-0829, Placebo (NNC0247-0829)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas